Abstract:The human riboflavin (RF) transporter-3 (hRFVT-3; product of the SLC52A3 gene) plays an essential role in the intestinal RF absorption process and is expressed exclusively at the apical membrane domain of polarized enterocytes. Previous studies have characterized different physiological/biological aspects of this transporter, but nothing is known about the glycosylation status of the hRFVT-3 protein and role of this modification in its physiology/biology. Additionally, little is known about the residues in the hRFVT-3 protein that interact with the ligand, RF. We addressed these issues using appropriate biochemical/molecular approaches, a protein-docking model, and established intestinal/renal epithelial cells. Our results showed that the hRFVT-3 protein is glycosylated and that glycosylation is important for its function. Mutating the predicted N-glycosylation sites at Asn94 and Asn168 led to a significant decrease in RF uptake; it also led to a marked intracellular (in the endoplasmic reticulum, ER) retention of the mutated proteins as shown by live-cell confocal imaging studies. The protein-docking model used in this study has identified a number of putative substrate-interacting sites: Ser16, Ile20, Trp24, Phe142, Thr314, and Asn315 Mutating these potential interacting sites was indeed found to lead to a significant inhibition in RF uptake and to intracellular (ER) retention of the mutated proteins (except for the Phe142 mutant). These results demonstrate that the hRFVT-3 protein is glycosylated and this glycosylation is important for its function and cell surface expression. This study also identified a number of residues in the hRFVT-3 polypeptide that are important for its function/cell surface expression.

Substrate and drug recognition mechanisms of SLC19A3

Structural basis of substrate transport and drug recognition by the human thiamine transporter SLC19A3

Structural basis of thiamine transport and drug recognition by SLC19A3

Molecular Mechanism of Substrate Recognition by Folate Transporter SLC19A1

Substrate binding plasticity revealed by Cryo-EM structures of SLC26A2

Dimeric transport mechanism of human vitamin C transporter SVCT1

Structural Basis for Substrate and Inhibitor Recognition of Human Multidrug Transporter MRP4

Structural Mechanisms of Human Sodium-Coupled High-Affinity Choline Transporter CHT1

Structural Basis of Vitamin C Recognition and Transport by Mammalian SVCT1 Transporter

Structure/functional aspects of the human riboflavin transporter-3 (SLC52A3): role of the predicted glycosylation and substrate-interacting sites

Non-canonical substrate recognition by the human WDR26-CTLH E3 ligase regulates prodrug metabolism

SLC7A11/xCT in Cancer: Biological Functions and Therapeutic Implications.

Molecular mechanism of choline and ethanolamine transport in humans

Structural Insights into the Gating Mechanism of Human SLC26A9 Mediated by Its C-terminal Sequence

Molecular basis of inhibition of the amino acid transporter B0AT1 (SLC6A19)

Structural insights into human organic cation transporter 1 transport and inhibition

Molecular basis of inhibition of the amino acid transporter B AT1 (SLC6A19)

Structural Insights into the Conformational Changes of BTR1/SLC4A11 in Complex with PIP 2

Drug inhibition and substrate alternating flipping mechanisms of human VMAT2

The dimer of human SVCT1 is key for transport function

Structural basis of the excitatory amino acid transporter 3 substrate recognition